Masonic Cancer Center, University of Minnesota: Leukemia, Myeloid, Acute trials
The registry lists 32 Leukemia, Myeloid, Acute studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 7 are open to participants now and 13 have results posted.
Phase 1 10Phase 2 21No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCTRecruitingNCT07591649Phase 1/2
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesRecruitingNCT07493538Phase 2
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingNCT07008638Phase 1/2
- HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AMLRecruitingNCT06594445Phase 1
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedNCT04714372Phase 1Results posted
- A Study of FMT in Patients With AML Allo HSCT in RecipientsCompletedNCT03678493Phase 2Results posted
- Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
- Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCTCompletedNCT02989844Phase 2Results posted
- UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
- MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML PatientsCompletedNCT02395822Phase 2Results posted
- IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
- T-Cell Depleted Double UCB for Refractory AMLTerminatedNCT01464359Phase 2Results posted
- Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)TerminatedNCT01106950Phase 2Results posted
- Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
- Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell TransplantCompletedNCT00303667Phase 1/2Results posted
- Study of Periodontitis and Blood Stream Infection in AML Patients Receiving ChemotherapyTerminatedNCT04858594
- Diagnosis and Treatment of Periodontal Disease in Patients With AMLWithdrawnNCT04530695Not applicable
- Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive ChemotherapyCompletedNCT03728699
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AMLCompletedNCT03081780Phase 1
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete RemissionWithdrawnNCT01639456Phase 2
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)CompletedNCT01385423Phase 1
- Selecting a Favorable KIR Donor in Unrelated HCT for AMLCompletedNCT01288222Not applicable
- AHN-12 Biodistribution in Advanced LeukemiaTerminatedNCT01207076Phase 1